HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAsafety guidance72% confidence

Field Safety Notices: 8 -12 June 2026

Source: MHRA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Amgen.

Regulatory Analysis

List of Field Safety Notices for 8-12 June 2026

Supporting Context

Therapeutic area
Respiratory · Asthma
Sub-indication
Ild

Related signal: Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients

Source

View source document

Related Signal

Open signal — Amgen's AMG 691 Phase 1 Study Targets Safety in Asthma Patients
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.